We suggest that these agents be further tested as adjuvants to insulin therapy in T1D to help reduce the occurrence of iatrogenic hypoglycaemia and the risks it poses.<h4>Funding</h4>Supported by The Leona M. and Harry B. Helmsley Charitable Trust. The gene discussed is INS; the disease is type 1 diabetes mellitus.